CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Inotiv Secures MilliporeSigmas...

GHO Acquires Velocity Clinical Research

Life Sciences Review Life Sciences Review | Thursday, May 13, 2021
Tweet

Velocity Clinical Research has agreed with Global Healthcare Opportunities to be acquired from NaviMed Capital and other investors. 


FREMONT, CA: Velocity Clinical Research (Velocity), a leading integrated clinical trial site organization, recently announced that it has signed an agreement with Global Healthcare Opportunities, or GHO Capital (GHO), the European specialist investor in healthcare, to be purchased from NaviMed Capital (NaviMed) and other investors, demonstrating how the business of operating clinical trial sites are transforming.


Velocity, headquartered in Durham, North Carolina, functions in 16 fully-owned sites in 11 US states. The company primarily conducts phase II and phase III clinical trials to support biopharmaceutical and contract research organization (CRO) clients' global drug development programs. Velocity has worked with almost 200 biopharmaceutical clients in three years, including most of the top ten pharmaceutical sponsors, and its sites have conducted almost 5,000 clinical trials.


Velocity's sites are entirely integrated through a centralized infrastructure and shared technology backbone, enabling superior patient enlistment and continuous, high-quality data delivery. 


The buyout of Velocity marks the next phase in the rapidly evolving clinical trial site landscape, which has traditionally been highly fragmented even after the biopharmaceutical industry spends almost $15 billion in annual investigator fees.


Dr. G. Paul Evans, Chief Executive and President of Velocity Clinical Research said, "Today's announcement signals the future for the clinical trials industry. Velocity's model was put to the test last year during the race to find a COVID vaccine, demonstrating that our integrated approach to running clinical sites is head and shoulders above others. We have been more agile and quicker to adapt in response to the needs of both CROs and patients."


"NaviMed has been a great partner for us, working with us on the direction for the company while giving our senior management team the freedom to execute on strategic decisions. The business of owning clinical trial sites is changing and its difficult for other companies to scale in this space. Our experienced team knows how to run sites and we feel that GHO is the right partner to back Velocity, as we move into our next phase of growth thanks to their experience in pharmaceutical services."


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/gho-acquires-velocity-clinical-research--nwid-357.html